Journal Article10.1016/J.EJMECH.2017.07.027
Design, synthesis and antiproliferative activity of decarbonyl luotonin analogues
Abdulrahman I. Almansour,Natarajan Arumugam,Raju Suresh Kumar,Sakkarapalayam M. Mahalingam,Samaresh Sau,Giulia Bianchini,J. Carlos Menéndez,Mohammad Altaf,Hazem A. Ghabbour +8 more
40
TL;DR: A small library of benzimidazole-fused pyrrolo[3,4-b]quinoline has been synthesized from readily available benzimids and various substituted arylamines in good to excellent yields utilizing an intramolecular Povarov reaction catalyzed by boron trifluoride diethyl etharate as the key final step.
read more
About: This article is published in European Journal of Medicinal Chemistry. The article was published on 29 Sep 2017. The article focuses on the topics: Camptothecin & Povarov reaction.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade.
Xiaoxia Liang,Wu Qiang,Shangxian Luan,Zhongqiong Yin,Changliang He,Lizi Yin,Yuanfeng Zou,Yuan Zhixiang,Lixia Li,Xu Song,Min He,Cheng Lv,Wei Zhang +12 more
TL;DR: This review summarizes types of topoisomerase inhibitors in the past decade, and divides them into nine classes by structural characteristics, including N-heterocycles compounds, quinone derivatives, flavonoids derivatives, coumarin derivatives, lignan derivatives, polyphenol derivatives, diterpenes derivatives, fatty acids derivatives, and metal complexes.
184
Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers.
Kaustubh A. Gawde,Samaresh Sau,Katyayani Tatiparti,Sushil K. Kashaw,Mohammad Mehrmohammadi,Asfar S. Azmi,Arun K. Iyer,Arun K. Iyer +7 more
TL;DR: Preliminary studies show a promising nanomedicine platform for combination therapy for leading gynecological tumor, such as ovarian and cervical cancer.
88
Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy.
Kang Xiong,Yan Zhang,Qian Wen,Jia Luo,Yun Lu,ZhouXue Wu,BiQiong Wang,Yue Chen,Ling Zhao,ShaoZhi Fu +9 more
TL;DR: The present study suggests that the DDS PTX-CUR-NPs could be employed for the effective treatment of breast cancers in near future.
71
Development of asialoglycoprotein receptor directed nanoparticles for selective delivery of curcumin derivative to hepatocellular carcinoma.
TL;DR: A proof-of-concept study using nanoscale PAMAM-Gal dendrimer has demonstrated its competency as an efficient delivery system for selective delivery of potent CDF for HCC anticancer therapy as well as HCC diagnosis via NIR imaging.
51
Topoisomerase I inhibitors: Challenges, progress and the road ahead.
TL;DR: Topoisomerase IB (Top1) enzymes are expressed much higher in several tumor cells and therefore, modulating the activity of Top1 in tumor cells to prevent DNA replication and subsequent cell division made it an important drug target for anticancer therapy as discussed by the authors .
47
References
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.
Rajesh Krishna,Lawrence D. Mayer +1 more
TL;DR: In this paper, a review of P-glycoprotein (P-GP)-mediated pharmacokinetic interactions is presented, where the relevance of these drug transport proteins in the context of pharmacokinetics implications (drug absorption, distribution, clearance, and interactions) is discussed.
1.1K
The mechanism of topoisomerase I poisoning by a camptothecin analog
Bart L. Staker,Kathryn Hjerrild,Michael D. Feese,Craig A. Behnke,Alex B. Burgin,Lance Stewart +5 more
TL;DR: The x-ray crystal structure of human topoisomerase I covalently joined to double-stranded DNA and bound to the clinically approved anticancer agent Topotecan suggests that there are at least two classes of mutations that can produce a drug-resistant enzyme.
839
Drugging Topoisomerases: Lessons and Challenges
TL;DR: This review discusses how topoisomerase inhibitors kill cells by trapping topoisomersases on DNA rather than by classical enzymatic inhibition, and extends to a novel mechanism of action of PARP inhibitors and could be applied to the targeting of transcription factors.
DNA Topoisomerase I Inhibitors: Chemistry, Biology and Interfacial Inhibition
TL;DR: DNA topoisomerases I and II (Top1 and Top2) are established molecular targets of anticancer drugs and eukaryotic Top1 enzymes belong to the broader family of site-specific tyrosine recombinases of prokaryotes and yeast.
Cancer therapies utilizing the camptothecins: a review of the in vivo literature.
TL;DR: This review summarizes the in vivo assessment-preliminary, preclinical, and clinical-of chemotherapeutics derived from camptothecin or a derivative, specifically in the context of biodistribution, dosing regimens, and pharmacokinetics with the desire of providing a useful source of comparative data.